Off-label use of orphan medicinal products: a Belgian qualitative study
نویسندگان
چکیده
BACKGROUND Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under well-defined circumstances. Moreover, a "Special Solidarity Fund" takes care of some specific cases eventually prescribed off-label. METHODS Semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the reimbursement of orphan medicinal products in Belgium. This task was performed by five last-year pharmacy students after having studied profoundly the medical literature around off-label prescribing. They had no previous contact with the participants. RESULTS Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated, if the on-label indication is rather general and when all other options have failed in some specific, evidence-based indications, especially in children. Before starting off-label use, the patient/family needs to be fully and clearly informed. The treatment is not reimbursed but sometimes sponsored by the company or by charity funds. Reporting of the outcome is necessary to avoid losing valuable information. The prescriber is responsible and can be held accountable. CONCLUSIONS While there is support from physicians and reimbursement experts, there is also concern in case of off-label use, mainly for reasons of patient safety especially when medicinal products are prescribed off-label in the absence of medical or scientific justification and driven by cost-containment motives.
منابع مشابه
Understanding off-label use and the new challenges
As there are several thousands of rare disorders and only some tents of orphan drugs authorized in Europe, off-label use of medicinal products occurs frequently in the diagnosis, prevention and treatment of rare diseases. Off-label use is the use of a medicinal product for another indication, another patient group, another dose or by another route of administration as indicated in the package i...
متن کاملOrphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
BACKGROUND Regulatory and economic frameworks stimulated the research and development of orphan drugs, but very little has been done for devices necessary for the in-vivo diagnosis, prevention and treatment of life-threatening conditions with a low prevalence/incidence. DISCUSSION A general public consultation in Europe has shown a positive attitude towards an "orphan device" directive. The U...
متن کاملUse and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
BACKGROUND Most of the drugs used in anesthesia are off-label in children even if they present solid clinical evidence in adults. This lack of authorization is caused by multiple factors including the difficulty in conducting research in this area (due to the ethical concerns and/or the low number of available participants, the high variability of the outcome measures) and the lack of economic ...
متن کاملThe Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
INTRODUCTION The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales. METHODS We assessed prescription patterns for four top-selling orphan drugs: lidocaine patch (Lidoderm) approved for post-herpe...
متن کاملEssential drugs for infants and children: European perspective.
It is difficult to draw up a list of medicines that are essential for infants and children. It is clear, however, that many of the medicines used appropriately to treat infants and children are not licensed for such use.1 The medicines concerned may be used outside the terms of their product license, ie, used off-label, or unlicensed for use in children at any age.2 Off-label use appears to be ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2016